| Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity SC Khojasteh, S Prabhu, JR Kenny, JS Halladay, AYH Lu European journal of drug metabolism and pharmacokinetics 36, 1-16, 2011 | 167 | 2011 |
| Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies Y Chen, JY Jin, S Mukadam, V Malhi, JR Kenny Biopharmaceutics & drug disposition 33 (2), 85-98, 2012 | 127 | 2012 |
| Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes DF McGinnity, AJ Berry, JR Kenny, K Grime, RJ Riley Drug metabolism and disposition 34 (8), 1291-1300, 2006 | 125 | 2006 |
| Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells DF McGinnity, G Zhang, JR Kenny, GA Hamilton, S Otmani, KR Stams, ... Drug metabolism and disposition 37 (6), 1259-1268, 2009 | 117 | 2009 |
| In vitro–in vivo extrapolation of clearance: Modeling hepatic metabolic clearance of highly bound drugs and comparative assessment with existing calculation methods P Poulin, JR Kenny, CECA Hop, S Haddad Journal of pharmaceutical sciences 101 (2), 838-851, 2012 | 116 | 2012 |
| Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis A Atkinson, JR Kenny, K Grime Drug metabolism and disposition 33 (11), 1637-1647, 2005 | 116 | 2005 |
| Syntheses and characterization of the acyl glucuronide and hydroxy metabolites of diclofenac JR Kenny, JL Maggs, X Meng, D Sinnott, SE Clarke, BK Park, ... Journal of medicinal chemistry 47 (11), 2816-2825, 2004 | 116 | 2004 |
| Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors JJ Kulagowski, W Blair, RJ Bull, C Chang, G Deshmukh, HJ Dyke, ... Journal of Medicinal Chemistry 55 (12), 5901-5921, 2012 | 104 | 2012 |
| Drug–Drug Interaction Potential of Marketed Oncology Drugs: In Vitro Assessment of Time-Dependent Cytochrome P450 Inhibition, Reactive Metabolite Formation … JR Kenny, S Mukadam, C Zhang, S Tay, C Collins, A Galetin, ... Pharmaceutical research 29, 1960-1976, 2012 | 101 | 2012 |
| A physiologically based pharmacokinetic modeling approach to predict disease–drug interactions: suppression of CYP3A by IL‐6 KK Machavaram, LM Almond, A Rostami‐Hodjegan, I Gardner, M Jamei, ... Clinical Pharmacology & Therapeutics 94 (2), 260-268, 2013 | 98 | 2013 |
| Prediction of drug-drug interactions arising from CYP3A induction using a physiologically based dynamic model LM Almond, S Mukadam, I Gardner, K Okialda, S Wong, O Hatley, S Tay, ... Drug Metabolism and Disposition 44 (6), 821-832, 2016 | 93 | 2016 |
| Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors EJ Hanan, A van Abbema, K Barrett, WS Blair, J Blaney, C Chang, ... Journal of medicinal chemistry 55 (22), 10090-10107, 2012 | 86 | 2012 |
| Drug concentration asymmetry in tissues and plasma for small molecule–related therapeutic modalities D Zhang, CECA Hop, G Patilea-Vrana, G Gampa, HK Seneviratne, ... Drug Metabolism and Disposition 47 (10), 1122-1135, 2019 | 85 | 2019 |
| Critical review of preclinical approaches to investigate cytochrome P450–mediated therapeutic protein drug-drug interactions and recommendations for best practices: A white paper R Evers, S Dallas, LJ Dickmann, OA Fahmi, JR Kenny, E Kraynov, ... Drug Metabolism and Disposition 41 (9), 1598-1609, 2013 | 82 | 2013 |
| Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2 M Zak, CA Hurley, SI Ward, P Bergeron, K Barrett, M Balazs, WS Blair, ... Journal of medicinal chemistry 56 (11), 4764-4785, 2013 | 77 | 2013 |
| Microphysiological systems for ADME-related applications: current status and recommendations for system development and characterization S Fowler, WLK Chen, DB Duignan, A Gupta, N Hariparsad, JR Kenny, ... Lab on a Chip 20 (3), 446-467, 2020 | 72 | 2020 |
| Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition BS Safina, S Baker, M Baumgardner, PM Blaney, BK Chan, YH Chen, ... Journal of medicinal chemistry 55 (12), 5887-5900, 2012 | 72 | 2012 |
| Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl … H Wong, JZ Chen, B Chou, JS Halladay, JR Kenny, H La, JC Marsters Jr, ... Xenobiotica 39 (11), 850-861, 2009 | 66 | 2009 |
| Comparative assessment of in vitro–in vivo extrapolation methods used for predicting hepatic metabolic clearance of drugs P Poulin, CECA Hop, Q Ho, JS Halladay, S Haddad, JR Kenny Journal of pharmaceutical sciences 101 (11), 4308-4326, 2012 | 62 | 2012 |
| Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2 M Zak, R Mendonca, M Balazs, K Barrett, P Bergeron, WS Blair, C Chang, ... Journal of Medicinal Chemistry 55 (13), 6176-6193, 2012 | 58 | 2012 |
